Kite/Gilead Yescarta Only CAR T-Cell Therapy with Durable Response, Survival in Non-Hodgkin Lymphomas

 – ZUMA-5 Analysis Shows Median Progression-Free Survival of 62.2 Months and Median Duration of Response of 60.4 Months After Median Follow-Up of More Than Five Years –

– Over Half of Patients Alive at Time of Analysis, with No Need for Subsequent Therapy and Rare Instances of Late Disease Progression, Indicating Curative Potential –

https://www.businesswire.com/news/home/20241209207499/en